Methods for diagnosis of myelodysplastic syndromes (MDS)
First Claim
Patent Images
1. A method of ascertaining response to a therapy regimen in a subject diagnosed with myelodysplastic syndrome, comprising:
- obtaining a blood sample from the subject at a timepoint during or after said therapy regimen;
measuring and analyzing a set of predictive parameters in leukocytes from the blood sample of the subject using flow cytometry, wherein said set of predictive parameters comprises polymorphic neutrophil (PMN) granularity and leucocyte expression of CD66, CD11a, CD10, and CD116;
assigning a numerical value to each predictive parameter;
assigning a numerical score reflecting the predictive parameter values obtained for said leucocytes in said blood sample;
comparing the predictive parameters to corresponding predictive parameters for a control sample taken from said subject obtained prior to the initiation of, or earlier than said timepoint in, said therapy regimen, or a combination thereof;
and assigning a numerical score reflecting predictive parameter values obtained for the control sample, wherein a decrease in the subject'"'"'s numerical score in comparison to the control sample indicates the subject'"'"'s responsiveness to said therapy regimen.
1 Assignment
0 Petitions
Accused Products
Abstract
The present invention relates to methods and kits for diagnosing, ascertaining the clinical course of myelodysplastic syndrome (MDS) and ascertaining response to a therapy regimen of myelodysplastic syndrome. Specifically the invention provides methods and kits useful in the diagnosis and determination of clinical parameters associated with MDS based on surface markers unique to MDS.
-
Citations
8 Claims
-
1. A method of ascertaining response to a therapy regimen in a subject diagnosed with myelodysplastic syndrome, comprising:
-
obtaining a blood sample from the subject at a timepoint during or after said therapy regimen; measuring and analyzing a set of predictive parameters in leukocytes from the blood sample of the subject using flow cytometry, wherein said set of predictive parameters comprises polymorphic neutrophil (PMN) granularity and leucocyte expression of CD66, CD11a, CD10, and CD116; assigning a numerical value to each predictive parameter; assigning a numerical score reflecting the predictive parameter values obtained for said leucocytes in said blood sample; comparing the predictive parameters to corresponding predictive parameters for a control sample taken from said subject obtained prior to the initiation of, or earlier than said timepoint in, said therapy regimen, or a combination thereof; and assigning a numerical score reflecting predictive parameter values obtained for the control sample, wherein a decrease in the subject'"'"'s numerical score in comparison to the control sample indicates the subject'"'"'s responsiveness to said therapy regimen. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8)
-
Specification